MedTrace Logo

MEDITOXIN® in Treatment of Crow's Feet Line

NCT03317574 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2019-03-27

No results posted yet for this study

Summary

to determine the efficacy and safety of Meditoxin® in treatment of crow's feet line

Conditions

  • Crow's Feet Lines

Interventions

DRUG

botulinum toxin type A

24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas

DRUG

botulinum toxin type A

24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas

Sponsors & Collaborators

  • Medy-Tox

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-17
Primary Completion
2017-12-01
Completion
2018-05-14

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03317574 on ClinicalTrials.gov